Bradford D. Dahms - 30 Nov 2022 Form 4 Insider Report for Theseus Pharmaceuticals, Inc.

Role: Chief Financial Officer
Signature: /s/ Bradford Dahms
Issuer symbol: N/A
Transactions as of: 30 Nov 2022
Net transactions value: +$10,000
Form type: 4
Filing time: 01 Dec 2022, 15:35:05 UTC
Previous filing: 23 Feb 2022
Next filing: 21 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	THRX	Common Stock	Purchase	$10,000	+1,502	+32%	$6.66	6,142	30 Nov 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price of shares purchased. These shares were purchased in multiple transaction at prices ranging from $6.56 to $6.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
F2	Includes 1,162 shares and 1,508 shares previously purchased under the Issuer's 2021 Employee Stock Purchase Plan on May 13, 2022 and November 14, 2022, respectively.

Content

The price reported is a weighted average price of shares purchased. These shares were purchased in multiple transaction at prices ranging from $6.56 to $6.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.

Includes 1,162 shares and 1,508 shares previously purchased under the Issuer's 2021 Employee Stock Purchase Plan on May 13, 2022 and November 14, 2022, respectively.